The first vaccine that is likely to be authorized by the Food and Drug Administration, made by Pfizer, comes with especially daunting logistical challenges, including the fact that every recipient will need a booster shot three weeks after the initial dose. Keeping track of which people need the follow-up dose, and getting them to return for it, are among the steepest hurdles that public health officials face. So is a requirement that providers report, for every dose administered, demographic and other data to their state within 24 hours; states, in turn, will quickly report it to the CDC.
Missing from state plans to distribute COVID-19 vaccine: money
